细胞融合上调调节PD-L1表达,以逃避免疫监测
Youichi Tajima1, Futoshi Shibasaki2, Hisao Masai3
1Genome Dynamics Project, Department of Basic Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. tajima-yi@igakuken.or.jp.
Cancer gene therapy
|November 22, 2023
概括
介质细胞干细胞 (MSC) 与膀癌细胞融合,产生不稳定,快速生长的瘤. 这种细胞融合通过诱导PD-L1促进瘤形成,提供新的癌症免疫治疗点.
科学领域:
- 癌症生物学 癌症生物学
- 干细胞生物学 干细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 介质细胞干细胞 (MSC) 对于组织修复至关重要,但很少与体细胞融合.
- 与骨髓衍生MSCs (BM-MSCs) 共同培养的膀癌细胞 (UMUC-3) 显示了~5%的融合率.
- 这些融合细胞保持了高瘤性.
研究的目的:
- 研究细胞融合促进瘤发生的机制.
- 为了确定MSC-癌细胞融合产品中的遗传和分子变化.
- 探索细胞融合诱导的向途径的治疗潜力.
主要方法:
- 膀癌细胞UMUC-3与BM-MSCs的共同培养.
- 11个融合细胞克隆的建立和表征.
- 基因组分析 (Mb级删除,副本数量的增加).
- 试管体内生长和固独立生长测试.
- 在小鼠模型中进行异种移植实验.
- 基因表达分析和改变基因的识别.
- PD-L1淘汰赛实验和细胞因子表达的分析 (CCL2).
主要成果:
- 融合细胞表现出癌细胞删除的损失,但保留了复制数的增加,表明基因组不稳定性与3极.
- 融合细胞在体外表现出增强的增殖,独立于 anchorage 的生长,以及在体内有效的瘤形成.
- 在融合细胞中,有264个基因被特别改变,包括干扰素刺激基因 (ISG).
- 诱导PD-L1是独立于STAT1的,由基因素修饰调节,可能抑制巨细胞化.
- 过度表达CCL2通过产生瘤相关巨细胞 (TAMs) 来促进瘤进展.
结论:
- MSCs和膀癌细胞之间的细胞融合通过基因组不稳定性和改变基因表达促进瘤发生.
- 在融合细胞中诱导PD-L1表达有助于免疫逃避.
- CCL2介导的TAM招募进一步推动了瘤的进展.
- 这些发现揭示了将细胞融合与瘤发生联系起来的新机制,并突出了PD-L1作为癌症免疫治疗中的潜在治疗标.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K


